Repurposing anticancer drugs for the management of COVID-19 - European Journal of Cancer
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance | Science Translational Medicine
Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma | Nature Communications
Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis | HTML
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
Significant inhibitory effect of ruxolitinib in vivo. (A) Flow chart of... | Download Scientific Diagram
TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance - ScienceDirect
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy - ScienceDirect
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance - ScienceDirect
Ruxolitinib (INCB018424) Datasheet
Ruxolitinib enhanced the anti-tumor activity of chemotherapy agents in... | Download Scientific Diagram
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice | Scientific Reports
Ruxolitinib Plus Radiation and Temozolomide for Newly Diagnosed Grade III Gliomas and Glioblastoma | PracticeUpdate
JCI - Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway
JCI - Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
Survival is improved for VSV-IFNβ with the addition of ruxolitinib in a... | Download Scientific Diagram
A STAT3-based gene signature stratifies glioma patients for targeted therapy | Nature Communications
Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regu
Ruxolitinib Phosphate Datasheet
Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor - Network of Cancer Research
Targeting the JAK/STAT pathway in solid tumors
